Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Israel

Mylan Eyes Generic Version Of Copaxone

June 2008 | Company News Alert

US-based Mylan has signed an agreement with India's NATCO Pharma to market a generic version of Israeli drugmaker Teva's multiple sclerosis drug Copaxone (glatiramer) in the US, Europe, Australia, New Zealand, Japan and

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *

Forgotten your password?

If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Related Insight Articles
Teva To Acquire Barr

Companies / Israel Not to be outdone by its research-focused rivals, Israel's Teva Pharmaceutical Industries has once again demonstrated its desire to expand by acquisition, launching a US$7.46bn bid for US-based generics...
July 2008
Sun Pharma Plans Hostile Takeover Of Taro

Companies / Israel Following the rejection of its merger agreement with Israel-based drug manufacturer Taro Pharma , India's Sun Pharma has launched a hostile takeover bid.
July 2008
Momenta's Generic Version Of Copaxone To Be Reviewed

Companies / Israel The US FDA has accepted for review Momenta Pharmaceuticals' generic version of Teva Pharmaceutical's Copaxone (glatiramer).
July 2008
Sun Ups Stake In Taro

Companies / Israel In a move that BMI interprets as a signal that India's Sun Pharmaceutical Industries is growing impatient with opposition to its proposed acquisition of Israel's Taro Pharmaceutical Industries from some...
February 2008
Teva, Pfizer In Generics Pact

Companies / Israel Leading generic drug company Teva and US R&D-based major Pfizer have agreed to settle all outstanding litigation regarding three top-selling compounds. The deal refers to cancer drug Idamycin (idarubicin),...
November 2006
Middle East & Africa InsightMiddle East & Africa Channels Middle East & Africa Countries


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2008 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS